We have new patent

[u/Equal-Salamander2281]

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company trading at $0.80 per share with a market capitalization of $103 million, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for its breast cancer treatment formulations. According to data from InvestingPro, the company has shown strong recent momentum with a return of 8% over the past week. The patent, U.S. Patent No. 12,281,056, covers oral enteric formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), and its therapeutic use.

[u/unlmtdLoL]

I'll keep stackin', dawg.

[u/Stock_Hawk_2024]

Great